Star Center

Recent papers from Star Center

1. Chromosomal and Genetic Causes of Primary Ovarian Insufficiency in the Utah PopulationJournal of the Endocrine Society · 2026
2. Somatic epimutations cap genetic determinism in the human diploid chromatin epigenomeCell · 2026
3. Adverse Events Associated with Continuous Positive Airway Pressure and Related Positive Airway Pressure Devices: A Narrative Review and Rationale for Closer MonitoringIndian Journal of Sleep Medicine · 2026
4. Environmental Exposure to Endocrine-Disrupting Chemicals and SARS-CoV-2 Infection History Among Blood DonorsLife · 2026
5. Staff training as a mechanism to improve the use of non-pharmacological interventions for Behaviours that Challenge in dementiaFPOP Bulletin Psychology of Older People · 2026
6. Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut AllergyActa Paediatrica · 2026
7. Optical downlink modeling for low-earth-orbit and medium-earth-orbit satellites under atmospheric turbulence with a quantum-state-tomography use casePhysical Review A · 2026
8. 169TiP A phase I first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-901 as monotherapy and in combination with bevacizumab (Bev) in adult patients with platinum-resistant ovarian cancer (PROC)ESMO Open · 2026
9. Clinical Spectrum, independent risk factors, and treatment outcomes of pediatric arrhythmias: a multicenter retrospective analysis in XinjiangFrontiers in Pediatrics · 2026
10. BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
11. A first-in-human phase 1a study of LP-184, a tumor site–activated novel alkylating agent, in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
12. Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.Journal of Clinical Oncology · 2026
13. Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.Journal of Clinical Oncology · 2026
14. A phase 1, first-in-human study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy in advanced solid tumors and in combination with endocrine therapy in ER+, HER2− advanced breast cancer (ABC): Preliminary results.Journal of Clinical Oncology · 2026
15. Clinical evaluation of communication brain computer interfaces in amyotrophic lateral sclerosis: a landscape analysisFrontiers in Human Neuroscience · 2026
16. Abstract CT118: Clinical pharmacokinetic and pharmacodynamic of JBZ-001 (HOSU-53): Comparison of first-in-human data with translational preclinical predictionsCancer Research · 2026
17. Intracranial Pressure Treatment Thresholds in Pediatric Traumatic Brain InjuryJAMA Pediatrics · 2026
18. The NeuroRelational Framework Awake States Indicators Checklist: Preliminary Psychometrics for Use in Pediatric Occupational TherapyOccupational Therapy in Mental Health · 2026
19. The performance of genetic-constraint metrics varies significantly across the human noncoding genome2026
20. Integrated Approaches for Attenuation of Cr(VI) Toxicity in Chromite Mine WasteSoil and Sediment Contamination An International Journal · 2026